In a groundbreaking move, Novartis has received approval for Coartem® Baby, the first malaria treatment specifically designed for newborns and young infants, addressing a critical healthcare gap in malaria-endemic regions.
Swiss authorities have approved Coartem Baby, the first malaria treatment for newborns under 11 pounds, addressing a significant health gap for vulnerable infants. This sweet cherry-flavored drug can be mixed with breast milk, making it easier to administer.
